Influenza Season Articles & Analysis
17 news found
Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and ...
Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and ...
Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, shingles, Tdap, seasonal influenza and universal ...
Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, shingles, Tdap, seasonal influenza and universal ...
Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, shingles, Tdap, seasonal influenza and universal ...
Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, shingles, Tdap, seasonal influenza and universal ...
Further advancement of product candidates with CpG 1018 adjuvant through pre-clinical and clinical collaborations and additional discovery efforts, including ongoing partnership with Mount Sinai investigating universal and seasonal influenza. CpG 1018 Adjuvanted Shingles (Herpes Zoster) Vaccine Candidate Enters the Clinic Shingles is an extremely painful ...
Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, Tdap, seasonal influenza and universal ...
Micron’s technology was successfully evaluated in a Phase 1 clinical trial for seasonal influenza vaccination, the results of which were published in the peer-reviewed journal, The Lancet. ...
Predictions of which influenza strains will be circulating each year are made more than six months before the onset of flu season—and even if projections are accurate, unexpected strains can and do arise, rendering that year’s vaccine minimally effective. ...
This work leverages Micron’s technology, which has already been successfully evaluated in clinical studies including a Phase 1 trial of an FDA-approved seasonal influenza vaccine. Micron’s applicator-free technology is well-suited for the administration of vaccines and, in particular, for measles-rubella vaccination in low- and middle-income ...
“The preclinical results we have obtained make us confident in the ability of our IMX313P-based influenza vaccine candidate to improve the effectiveness of current seasonal influenza prevention,” said Alexandre Le Vert, Chief Executive Officer of Imaxio. ...
Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has been awarded a funding of EUR 600,000 (USD 772,000) by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project: “leveraging On t-cell immune resPonse To Improve influenza VACcines”. The aim of the OPTIVAC project is to improve the ...
The highest age specific ILI rates during week 11 2014 were in those aged 65 years and older; age specific rates in all other age groups decreased. Influenza positivity decreased during week 11 2014, with 84 (22.6%) influenza positive specimens reported from the NVRL: 54 influenza A(H3), 29 influenza A(H1)pdm09 and one ...
Update By Dr D J Gallagher, Employment Health Advisors (EHA). Influenza activity levels remained at low levels in Ireland during weeks 51 & 52 2013; however sporadic confirmed cases of influenza are being reported. ...
Because asthma was the most common underlying health condition among those hospitalized in the United States with 2009 H1N1 influenza infection during the 2009-2010 influenza season, NHLBI and NIAID conducted a collaborative study to establish safe and effective strategies to vaccinate children and adults with mild to severe asthma against the ...
Because asthma was the most common underlying health condition among those hospitalized in the United States with 2009 H1N1 influenza infection during the 2009-2010 influenza season, NHLBI and NIAID conducted a collaborative study to establish safe and effective strategies to vaccinate children and adults with mild to severe asthma against the ...